Fluvoxamine in the treatment of body dysmorphic disorder (dysmorphophobia)
The DOI matches its Crossref record.
Abstract
Fifteen consecutive patients with a DSM-III-R diagnosis of body dysmorphic disorder (BDD) were included in a 10-week open clinical trial of fluvoxamine. Treatment began at 100 mg/day fluvoxamine and was increased to a maximum of 300 mg/day or until intolerable side effects developed or a complete or nearly complete resolution of symptoms occurred. At baseline and at weeks 2, 6 and 10, patients completed the Hopkins Symptoms Check-List (HSCL-90) and a specific rating scale for BDD symptoms (BDDSS), and clinicians completed a Clinical Global Improvement Scale. Twelve of the 15 patients completed the trial. Of the three patients who did not complete the study, one improved moderately during the placebo phase, one showed a marked worsening of the depressive symptoms during the wash-out phase and one showed adverse side effects, such as nausea and diarrhoea, after the first week of treatment and was unable to continue the trial. After 10 weeks, of the 12 remaining patients, 10 were considered to be markedly improved, one minimally improved and one unchanged. Several outcome measures showed a significant improvement from baseline to week 10. Our findings suggest that fluvoxamine may be effective in the treatment of BDD. Double-blind studies will be required to investigate these findings further.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
A Randomized Placebo-Controlled Trial of Fluoxetine in Body Dysmorphic Disorder
Phillips, K. A., Albertini, R. S., & Rasmussen, S. A. (2002) · Archives of General Psychiatry · doi:10.1001/archpsyc.59.4.381 · Cited by 321
The high prevalence of “Soft” bipolar (II) features in atypical depression
Perugi, G., Akiskal, H. S., Lattanzi, L., Cecconi, D., Mastrocinque, C., Patronelli, A., Vignoli, S., & Bemi, E. (1998) · Comprehensive Psychiatry · doi:10.1016/s0010-440x(98)90080-3 · Cited by 304
Self-citationBody Dysmorphic Disorder and Cosmetic Surgery
Crerand, C. E., Franklin, M. E., & Sarwer, D. B. (2006) · Plastic and Reconstructive Surgery · doi:10.1097/01.prs.0000242500.28431.24 · Cited by 265
Phillips, K. A., & Hollander, E. (2008) · Body Image · doi:10.1016/j.bodyim.2007.12.003 · Cited by 214
Phillips, K. A., Keshaviah, A., Dougherty, D. D., Stout, R. L., Menard, W., & Wilhelm, S. (2016) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2016.15091243 · Cited by 75
Metadata
- Authors
- Perugi, G., Giannotti, D., Vaio, S. D., Frare, F., Saettoni, M., & Cassano, G. B.
- Venue
- International Clinical Psychopharmacology
- Published
- 1996-12
- Volume
- 11
- Issue
- 4
- Pages
- 247-254
- ISSN
- 0268-1315 (ISSN-L)
- OpenAlex
- W2090218217
- Cited by
- 109
- References
- 0
- FWCI
- 3.15
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Fluvoxamine in the treatment of body dysmorphic disorder (dysmorphophobia). https://app.cochat.ai/papers/10.1097/00004850-199612000-00006
- The paper
- Perugi, G., Giannotti, D., Vaio, S. D., Frare, F., Saettoni, M., & Cassano, G. B. (1996). Fluvoxamine in the treatment of body dysmorphic disorder (dysmorphophobia). International Clinical Psychopharmacology. https://doi.org/10.1097/00004850-199612000-00006
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.